Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight cycling) in the general population, which ...
The researchers theorise the protective effects of these drugs could be because they reduce inflammation, control infections ...
The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...
Adults with type 1 diabetes who partake in weight cycling and repeatedly lose and regain body weight are more likely to develop diabetic kidney disease, researchers reported in The Journal of Clinical ...
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...